Figures & data
Figure 1. Imaging data and CEA changes during the treatment of a patient with advanced GEJ cancer with multiple organ metastasis after surgery. The surgery is taken as the origin, and – or + indicates the month before or after the surgery, respectively (m: months). (a) the patient was diagnosed with gastroesophageal junction cancer. After receiving neoadjuvant therapy, surgery, pembrolizumab (P) for 2 cycles, trastuzumab (T)-targeted therapy for 36 cycles, and CIK cell immunotherapy 9 times, he survived 36.6 months after the diagnosis of postoperative metastases to the time at which this manuscript was submitted. (b) After the patient received two cycles of trastuzumab and pembrolizumab, his CEA decreased significantly and remained within the normal range during subsequent treatments.
